纳米粒子在乳腺癌诊断和治疗中的应用进展

doi:10.11904/j.issn.1002-3070.2025.02.011

摘要/Abstract

摘要： 乳腺癌是全球女性最常见的癌症之一,其诊断和治疗技术的不断进步对于提高患者生存率和生活质量至关重要。近年来,纳米技术的迅速发展为乳腺癌的诊断和治疗提供了新的策略。本文综述了纳米粒子在乳腺癌诊断和治疗中的应用进展,涵盖了乳腺癌成像、药物递送、基因治疗以及免疫治疗等多个方面,并展望其未来发展趋势。

关键词: 乳腺癌, 癌症治疗, 临床应用, 纳米技术

Abstract: Breast cancer is one of the most common cancers among women in the world,and the continuous progress of its diagnosis and treatment technology is crucial to improve the patient survival rates and quality of life.In recent years,the rapid development of nanotechnology has provided a new strategy for the diagnosis and treatment of breast cancer.This article summarizes the application progress of nanoparticles in the diagnosis and treatment of breast cancer,covering breast cancer imaging,drug delivery,gene therapy,and immunotherapy,and discusses the future development trend.

Key words: Breast cancer, Cancer treatment, Clinical applications, Nanotechnology

中图分类号:

R737.9

王帅, 黎其庆, 李瑞, 许铁峰. 纳米粒子在乳腺癌诊断和治疗中的应用进展[J]. 实用肿瘤学杂志, 2025, 39(2): 151-156.

WANG Shuai, LI Qiqing, LI Rui, XU Tiefeng. Advances in the application of nanoparticles in the diagnosis and treatment of breast cancer[J]. Journal of Practical Oncology, 2025, 39(2): 151-156.

参考文献

1 Luo W,Ali YF,Liu C,et al.Particle therapy for breast cancer:benefits and challenges[J].Front Oncol,2021,11:662826.
2 Prat A,Pineda E,Adamo B,et al.Clinical implications of the intrinsic molecular subtypes of breast cancer[J].Breast,2015,24:26-35.
3 Majeed W,Aslam B,Javed I,et al.Breast cancer:major risk factors and recent developments in treatment[J].Asian Pac J Cancer Prev,2014,15(8):3353-3358.
4 Kashyap A,Kumari M,Singh A,et al.Current development of theragnostic nanoparticles for women's cancer treatment[J].Biomed Mater,2024,19(4):042001.
5 Cheang MCU,Voduc D,Bajdik C,et al.Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype[J].Clin Cancer Res,2008,14(5):1368-1376.
6 Leidy J,Khan A,Kandil D.Basal-like breast cancer:update on clinicopathologic,immunohistochemical,and molecular features[J].Arch Pathol Lab Med,2014,138(1):37-43.
7 Ashrafizadeh M,Delfi M,Hashemi F,et al.Biomedical application of chitosan-based nanoscale delivery systems:Potential usefulness in siRNA delivery for cancer therapy[J].Carbohydr Polym,2021,260:117809.
8 Juan AS,Montembault A,Gillet D.Degradation of chitosan-based materials after different sterilization treatments.IOP Conf Ser[J].Mater Sci Eng C Mater Biol Appl,2012,31(1):1-5.
9 Chiu CF,Fu RH,Hsu S,et al.Delivery capacity and anticancer ability of the berberine-loaded gold nanoparticles to promote the apoptosis effect in breast cancer[J].Cancers,2021,13(21):5317.
10 Park SY,Chae SY,Park JO,et al.Gold-conjugated resveratrol nanoparticles attenuate the invasion and MMP-9 and COX-2 expression in breast cancer cells[J].Oncol Rep,2016,35(6):3248-3256.
11 Sadhukhan P,Kundu M,Chatterjee S,et al.Targeted delivery of quercetin via pH-responsive zinc oxide nanoparticles for breast cancer therapy[J].Mater Sci Eng C,2019,100:129-140.
12 Hussain Y,Mirzaei S,Ashrafizadeh M,et al.Quercetin and its nano-scale delivery systems in prostate cancer therapy:paving the way for cancer elimination and reversing chemoresistance[J].Cancers,2021,13(7):1602.
13 Salehiabar M,Ghaffarlou M,Mohammadi A,et al.Targeted CuFe2O4 hybrid nanoradiosensitizers for synchronous chemoradiotherapy[J].J Control Release,2023,353:850-863.
14 Niu S,Zhang X,Williams GR,et al.Hollow mesoporous silica nanoparticles gated by chitosan-copper sulfide composites as theranostic agents for the treatment of breast cancer[J].Acta Biomater,2021,126:408-420.
15 Wang J,Wang Y,Liu Q,et al.Rational design of multifunctional dendritic mesoporous silica nanoparticles to load curcumin and enhance efficacy for breast cancer therapy[J].ACS Appl Mater Interfaces,2016,8(40):26511-26523.
16 Li N,Wang Z,Zhang Y,et al.Curcumin-loaded redox-responsive mesoporous silica nanoparticles for targeted breast cancer therapy[J].Artif Cells Nanomed Biotechnol,2018,46(2):921-935.
17 Aghapour F,Moghadamnia AA,Nicolini A,et al.Quercetin conjugated with silica nanoparticles inhibits tumor growth in MCF-7 breast cancer cell lines[J].Biochem Biophys Res Commun,2018,500(4):860-865.
18 Zang X,Cheng M,Zhang X,et al.Quercetin nanoformulations:a promising strategy for tumor therapy[J].Food Funct,2021,12(15):6664-6681.
19 Kumari M,Sharma N,Manchanda R,et al.PGMD/curcumin nanoparticles for the treatment of breast cancer[J].Sci Rep,2021,11(1):3824.
20 Abdel-Hakeem MA,Mongy S,Hassan B,et al.Curcumin loaded chitosan-protamine nanoparticles revealed antitumor activity via suppression of NF-κB,proinflammatory cytokines and Bcl-2 gene expression in the breast cancer cells[J].J Pharm Sci,2021,110(9):3298-3305.
21 de Oliveira Pedro R,Hoffmann S,Pereira S,et al.Self-assembled amphiphilic chitosan nanoparticles for quercetin delivery to breast cancer cells[J].Eur J Pharm Biopharm,2018,131:203-210.
22 Chiu CF,Fu RH,Hsu S,et al.Delivery capacity and anticancer ability of the berberine-loaded gold nanoparticles to promote the apoptosis effect in breast cancer[J].Cancers,2021,13(21):5317.
23 Park SY,Chae SY,Park JO,et al.Gold-conjugated resveratrol nanoparticles attenuate the invasion and MMP-9 and COX-2 expression in breast cancer cells[J].Oncol Rep,2016,35(6):3248-3256.
24 Ghanbari N,Salehi Z,Khodadadi AA,et al.Glucosamine-conjugated graphene quantum dots as versatile and pH-sensitive nanocarriers for enhanced delivery of curcumin targeting to breast cancer[J].Mater Sci Eng C Mater Biol Appl,2021,121:111809.
25 Hatamie S,Akhavan O,Sadrnezhaad SK,et al.Curcumin-reduced graphene oxide sheets and their effects on human breast cancer cells[J].Mater Sci Eng C Mater Biol Appl,2015,55:482-489.
26 Hai L,He D,He X,et al.Facile fabrication of a resveratrol loaded phospholipid@ reduced graphene oxide nanoassembly for targeted and near-infrared laser-triggered chemo/ photothermal synergistic therapy of cancer in vivo[J].J Mater Chem B,2017,5(29):5783-5792.
27 Nasrollahi F,Koh YR,Chen P,et al.Targeting graphene quantum dots to epidermal growth factor receptor for delivery of cisplatin and cellular imaging[J].Mater Sci Eng C Mater Biol Appl,2019,94:247-257.
28 Ghamkhari A,Abbaspour-Ravasjani S,Talebi M,et al.Development of a graphene oxide-poly lactide nanocomposite as a smart drug delivery system[J].Int J Biol Macromol,2021,169:521-531.
29 Astani S,Salehi R,Massoumi B,et al.Co-delivery of cisplatin and doxorubicin by carboxylic acid functionalized poly(hydroxyethyl methacrylate)/reduced graphene nanocomposite for combination chemotherapy of breast cancer cells[J].J Biomater Sci Polym Ed,2021,32(5):657-677.
30 Chen H,Xing L,Guo H,et al.Dual-targeting SERS-encoded graphene oxide nanocarrier for intracellular co-delivery of doxorubicin and 9-aminoacridine with enhanced combination therapy[J].Analyst,2021,146(22):6893-6901.
31 Gharehdaghi Z,Rahimi R,Naghib SM,et al.Cu(II)-porphyrin metal-organic framework/graphene oxide:Synthesis,characterization,and application as a pH-responsive drug carrier for breast cancer treatment[J].JBIC J Biol Inorg Chem,2021,26:689-704.
32 Kurmi BD,Paliwal SR.Development and optimization of TPGS-based stealth liposome of doxorubicin using Box-Behnken design:characterization,hemocompatibility,and cytotoxicity evaluation in breast cancer cells[J].J Liposome Res,2022,32(2):129-145.
33 Darby RA,Callaghan R,McMahon RM.P-glycoprotein inhibition:the past,the present and the future[J].Curr Drug Metab,2011,12(8):722-731.
34 Yefimova SL,Kurilchenko IY,Tkacheva TN,et al.Comparative study of dye-loaded liposome accumulation in sensitive and resistant human breast cancer cells[J].Exp Oncol,2012,34(2):101-106.
35 Di H,Wu H,Gao Y,et al.Doxorubicin-and cisplatin-loaded nanostructured lipid carriers for breast cancer combination chemotherapy[J].Drug Dev Ind Pharm,2016,42(12):2038-2043.
36 Xu C,Xu J,Zheng Y,et al.Active-targeting and acid-sensitive pluronic prodrug micelles for efficiently overcoming MDR in breast cancer[J].J Mater Chem B,2020,8(13):2726-2737.
37 Jung H,Mok H.Mixed micelles for targeted and efficient doxorubicin delivery to Multidrug-Resistant breast cancer cells[J].Macromol Biosci,2016,16(5):748-758.
38 Guo S,Zhang X,Gan L,et al.Effect of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide)micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride:potential involvement of breast cancer resistance protein(ABCG2)[J].J Pharm Pharmacol,2010,62(8):973-984.
39 Agnello L,Tortorella S,d'Argenio A,et al.Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors[J].J Exp Clin Cancer Res,2021,40:1-17.
40 Banti CN,Raptopoulou CP,Psycharis V,et al.Novel silver glycinate conjugate with 3D polymeric intermolecular self-assembly architecture;an antiproliferative agent which induces apoptosis on human breast cancer cells[J].J Inorg Biochem,2021,216:111351.
41 Makvandi P,Chen M,Sartorius R,et al.Endocytosis of abiotic nanomaterials and nanobiovectors:Inhibition of membrane trafficking[J].Nano Today,2021,40:101279.
42 Ganji M,Dashtestani F,Neghab HK,et al.Gold nanoparticles conjugated L-lysine for improving cisplatin delivery to human breast cancer cells[J].Curr Drug Deliv,2021,18(6):753-760.
43 Zhou F,Feng B,Yu H,et al.Cisplatin prodrug-conjugated gold nanocluster for fluorescence imaging and targeted therapy of the breast cancer[J].Theranostics,2016,6(5):679.
44 Magalhaes M,Alvarez-Lorenzo C,Concheiro A,et al.RNAi-based therapeutics for lung cancer:biomarkers,microRNAs,and nanocarriers[J].Expert Opin Drug Deliv,2018,15(10):965-982.
45 Fu Z,Zhang X,Zhou X,et al.In vivo self-assembled small RNAs as a new generation of RNAi therapeutics[J].Cell Res,2021,31(6):631-648.
46 Kim MJ,Chang H,Nam G,et al.RNAi-based approaches for pancreatic cancer therapy[J].Pharmaceutics,2021,13(10):1638.
47 Kumar A,Singam A,Swaminathan G,et al.Combinatorial therapy using RNAi and curcumin nano-architectures regresses tumors in breast and colon cancer models[J].Nanoscale,2022,14(2):492-505.
48 Xin Y,Huang M,Guo W W,et al.Nano-based delivery of RNAi in cancer therapy[J].Mol Cancer,2017,16:1-9.
49 Taniguchi H,Natori Y,Miyagi Y,et al.Treatment of primary and metastatic breast and pancreatic tumors upon intravenous delivery of a PRDM14-specific chimeric siRNA/ nanocarrier complex[J].Int J Cancer,2021,149(3):646-656.
50 Maurer V,Altin S,Ag Seleci D,et al.In-vitro application of magnetic hybrid niosomes:targeted siRNA-delivery for enhanced breast cancer therapy[J].Pharmaceutics,2021,13(3):394.
51 Yang YY,Zhang W,Liu H,et al.Cell-penetrating peptide-modified graphene oxide nanoparticles loaded with rictor siRNA for the treatment of triple-negative breast cancer[J].Drug Des Devel Ther,2021,15:4961-4972.
52 Liang Z,Du L,Zhang E,et al.Targeted-delivery of siRNA via a polypeptide-modified liposome for the treatment of gp96 over-expressed breast cancer[J].Mater Sci Eng C,2021,121:111847.
53 Yuan Y,Li E,Zhao J,et al.Highly penetrating nanobubble polymer enhances LINC00511-siRNA delivery for improving the chemosensitivity of triple-negative breast cancer[J].Anti-Cancer Drugs,2021,32(2):178-188.

[1]	王锐, 马得原, 贾王强, 关泉林. 纳米医学介导的铜死亡在乳腺癌治疗中的应用和进展[J]. 实用肿瘤学杂志, 2025, 39(2): 144-150.
[2]	王铷, 张红霞. 磁共振成像技术在预测乳腺癌淋巴血管侵犯中的应用研究进展[J]. 实用肿瘤学杂志, 2025, 39(2): 162-168.
[3]	谷文, 周澜, 贾燕妮, 黄卫东. QLU-C10D量表在乳腺癌患者中测量属性的验证研究[J]. 实用肿瘤学杂志, 2025, 39(1): 49-55.
[4]	石长勇, 周紫珍, 周广林, 熊益敏. DCE-MRI定量参数联合NCAPH检测诊断早期乳腺癌的价值分析[J]. 实用肿瘤学杂志, 2025, 39(1): 56-60.
[5]	张宇晴, 荆晶, 刘兆良, 安静, 安巍巍. MZB1的可变剪接事件是乳腺癌内分泌治疗耐药的潜在生物标志物[J]. 实用肿瘤学杂志, 2024, 38(5): 313-322.
[6]	杨闽叶, 鲜童丞, 刘景建, 别俊, 王杰, 罗义. IL-23在乳腺癌组织中的表达及其与患者临床病理特征的相关性[J]. 实用肿瘤学杂志, 2024, 38(5): 323-329.
[7]	刘冬, 张太娟, 党计锋. 炎症反应驱动乳腺癌转移的研究进展[J]. 实用肿瘤学杂志, 2024, 38(5): 336-341.
[8]	李倩妮, 徐灵燕, 李健, 姚雪佩, 刘美娜. 乳腺癌多维治疗质量纵向评价的趋势分析[J]. 实用肿瘤学杂志, 2024, 38(4): 213-220.
[9]	高光强, 王发琳, 李娟, 田虹, 果思伽, 于晓兰, 杨婷婷, 刘家仁. β-紫罗兰酮通过NF-κB途径抑制乳腺癌细胞增殖[J]. 实用肿瘤学杂志, 2024, 38(4): 254-261.
[10]	邵禹铭, 朱坤兵, 张洁. SP/NK-1R系统在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(4): 268-272.
[11]	殷海燕, 淳志明, 马巧君, 成涵, 丁高恒, 张海燕, 刘玉琴. 2019年甘肃省肿瘤登记地区女性乳腺癌流行特征及2010-2019年趋势分析[J]. 实用肿瘤学杂志, 2024, 38(3): 141-148.
[12]	黑龙江省医学会乳腺肿瘤学组. 黑龙江省乳腺癌HER2低表达临床病理诊断专家共识(2024版)[J]. 实用肿瘤学杂志, 2024, 38(2): 71-78.
[13]	孟凡岗, 陈飞, 甄立军. DLX2对乳腺癌细胞增殖、迁移、侵袭、凋亡及乳腺癌干细胞特性的影响[J]. 实用肿瘤学杂志, 2024, 38(2): 88-95.
[14]	郑鹏飞, 董良鹏, 高延鑫, 张一夫, 秦双. 白细胞介素-38对乳腺癌患者CD8⁺T淋巴细胞功能的影响[J]. 实用肿瘤学杂志, 2024, 38(1): 30-36.
[15]	谢俊岭. 活化白细胞黏附分子在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(1): 45-49.